Буфенадрин

Создатель

Bufenadrine,Onbio Inc.

Производственный процесс

The ο-t-butyl-α-phenylbenzyl alcohol and N,N-dimethylmonochloroacetamide are dissolved in anhydrous diethyl ether. Portionwise 50% sodium hydride in the form of an oily suspension is added to the solution with stirring. After all the sodium hydride is added, the mixture is stirred at room temperature for another 3 h and then water is added to decompose excess sodium hydride. The ethereal layer is separated, dried with sodium sulfate, filtered and concentrated by removal of the solvent. The residue crystallizes upon addition of petroleum ether (boiling range 80-100°C) to which some diethyl ether is added. There is obtained 2-[ο-t-butyl-α-phenylbenzyl)oxy]-N,N-dimethyl acetamide, melting point 90-91°C (81% yield).
To a solution of 2-[ο-t-butyl-α-phenylbenzyl)oxy]-N,N-dimethyl acetamide in anhydrous diethyl ether is added portionwise with stirring and while refiuxing lithium aluminum hydride. After the addition is completed, refluxing is continued overnight. The reaction mixture still contains some lithium aluminum hydride which is decomposed by the addition of water. The mixture is filtered, the ethereal solution separated and dried over sodium sulfate. Diethyl ether is removed from the ethereal solution by distillation. There is obtained 2-[(ο-t-butyl-α-phenylbenzyl)oxy]-N,N-dimethylethylamine.

Терапевтическая функция

Antiemetic, Antihistaminic, Antiparkinsonian